Stocks
Erasca, Inc.ERAS
NASDAQHealthcareBiotechnology$14.39
Price as of · delayed, not real-time
A clinical-stage biotechnology company developing targeted therapies for patients with RAS/MAPK pathway-driven cancers, including solid tumors. Its lead programs focus on oral small molecules designed to inhibit key oncogenic drivers such as KRAS mutations. Investors track Erasca for its pipeline progress and upcoming clinical data readouts in a competitive precision oncology space.
52W Range: $2.10-$24.28
Congressional Interest in Erasca, Inc. (ERAS)
No congressional trades have been disclosed for Erasca, Inc. (ERAS) yet. All data is sourced from STOCK Act periodic transaction reports filed with Congress.
Total Disclosures
0
Unique Politicians
0
Buys
0
Sells
0
Who in Congress Is Trading ERAS?
No congressional trades found for this stock.